Yee Weng Wong

husband, father, HF doc & wannabe photographer

[Yee Weng Wong @YeeWengWong]

@CMCMarketsAusNZ can’t access my account the whole week
How am I supposed to trade?

[Yee Weng Wong @YeeWengWong]

Post AMI Shock

The comparison 10 years apart is sobering!

#ESC2023

[NEJM @NEJM]

HEART-FID trial results:

In patients with heart failure with reduced ejection fraction and iron deficiency, ferric carboxymaltose therapy did not appear to differ from placebo in the composite of death, heart-failure hospitalizations, or walk distance.

#ESCCongress

[NEJM @NEJM]

Late breaking at #ESCCongress: In patients with heart failure with preserved ejection fraction and obesity, semaglutide (2.4 mg) led to greater reductions in symptoms and physical limitations and greater improvements in exercise function than placebo. Full STEP-HFpEF trial:

[Yee Weng Wong @YeeWengWong]

Timely CRT upgrade for #HFrEF patients receiving >20% RV pacing is associated with HUGE improvements in clinical outcomes

Feels a bit vindicated overwhelming @DrHarisEP clinic with CRT upgrade referrals!

#ESC2023

[Sean van Diepen @seanvandiepen]

#ECLS-Shock trial shows no difference in all cause mortality with ECMO treatment in pts with AMI complicated by cardiogenic shock but higher risk of bleeding and peripheral ischemia. Congrats @thiele_holger @JasonKatzMD @agtruesdell @ShashankSinhaMD @ShelleyZieroth @carlosalviar

[Yee Weng Wong @YeeWengWong]

Let’s put #HeartFID in context

Baseline characteristics of patients in the randomized study to invest... https://t.co/7RKvlLKv5z

@JLHarrington_MD

[Yee Weng Wong @YeeWengWong]

Iron Deficiency in #HFrEF

On behalf of the Heart-FID study, we are pleased to share the results during #ESC and publication in #nejm. Pivotal step today in addressing an important patient need.

Clearly more to learn from the data!

https://t.co/NI0sETOrWO

[Adrian “WE NEED RCTS!” Hernandez @texhern]

Great presentation by @robmentz on HEART-FID

[Dr. Martha Gulati ♥️��❤️‍🩹🇨🇦 @DrMarthaGulati]

@robmentz presenting at #ESCCongress HEART-FID trial: ferric carboxymaltose in HFrEF & iron deficiency
🔺1/3 💃🏻
🔺safe therapy by this trial
🔺did not meet endpoint prespecified but ⬇️☠️+HF 🏥+ ⬆️6MWD
🔺FCM use in HFrEF: what will you do?
@DukeHeartCenter

[Robert Mentz, MD @robmentz]

Excited for #ESC2023 in just 2 wk!

Honored to share HEART-FID results on Sat, Aug 26 in Hotline 2 at 8:30am - on behalf of incredible investigator team & pts

Largest IV iron trial in HF

Followed by pooled FCM analysis

See ya there!

[Yee Weng Wong @YeeWengWong]

@DrRajeshG1 Severe AR. Rheumatic?

[Robert Mentz, MD @robmentz]

Such a privilege to share the results of TRANSFORM this morning. So much more to tell including insights on QOL, dose & data from ancillary studies

Slides and Lay Summary available at:
https://t.co/h1kUOort61

@DCRINews #AHA22 @SJGreene_md @mpsotka @dranulala

[Mayo Clinic AZ CV Fellows @MayoAZCVFellows]

A surprise party for our graduating Echo fellow, Dr. Weng Wong, as he returns home to Brisbane, Australia. Truly a spectacular talent, we can’t wait to see his accomplishments continue to accrue! @YeeWengWong @MayoClinic @MayoCVFellows #echofirst #heartsuccess #accfit #aussie

[Adrian “WE NEED RCTS!” Hernandez @texhern]

Care about children’s health, well-being and education?

Read this piece by ⁦@DCRINews⁩ faculty Kanecia Zimmerman and Danny Benjamin @NYTOpinion

https://t.co/7a1oIBwDVI
https://t.co/ns4vVyTKLq

[Yee Weng Wong @YeeWengWong]

Been an rewarding journey and so grateful to be part of a dedicated team!
New Cardiac Genomics service provides personalised medicine https://t.co/6f9jQIyIFr

[Gregg Fonarow MD @gcfmd]

HF 🏨 (overall 🏨, unique 🏨, and readmissions) have been increasing in US from 2014 onwards. Higher in 2017 compared to 2010.

@boback @HFSA

National Trends in HF Hospitalizations and Readmissions From 2010 to 2017 https://t.co/E8ENqlfCqD via @JAMACardio part of @JAMANetwork

[The New York Times @nytimes]

Throughout the pandemic, wrenching scenes have played out across the U.S. as doctors found themselves rationing a treatment in short supply — not ventilators, as initially feared, but a therapy called ECMO. https://t.co/JwjfwccZ8J

[Yee Weng Wong @YeeWengWong]

Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction | https://t.co/kJ35W71Koo https://t.co/HmjQwCNb1f